Steven M. Paul, Director at Sage Therapeutics, Inc. (SAGE), sold 20,000 shares at $71.36 ($1.4M) on 2015-06-01, disclosed to the SEC on 2015-06-02.
Scheduled sale ($1.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $71.36 | 8,705 | $621K | 42.9% |
| 2 | $72.06 | 3,291 | $237K | 16.4% |
| 3 | $73.13 | 4,604 | $337K | 23.3% |
| 4 | $74.05 | 3,400 | $252K | 17.4% |
| Total | $72.34 avg | 20,000 | $1.4M | 100% |
| Filing → |
| KRTX | BUY | 2021-08-18 | $501K | — | Filing → |
| ALNY | SELL | 2020-12-22 | $2.1M | — | Filing → |
| KRTX | SELL | 2020-06-30 | $60.5M | — | Filing → |